200,000+ products from a single source!
sales@angenechem.com
1350555-93-9 | N-[4-[(2R,4R,6S)-4-[[(4,5-Diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide
CAS No: 1350555-93-9 Catalog No: AG00A0NL MDL No:
Product Description
Catalog Number:
AG00A0NL
Chemical Name:
N-[4-[(2R,4R,6S)-4-[[(4,5-Diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide
CAS Number:
1350555-93-9
IUPAC Name:
N-[4-[(2R,4R,6S)-4-[(4,5-diphenyl-1,3-oxazol-2-yl)sulfanylmethyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide
InChI:
InChI=1S/C41H43N3O7S/c45-26-28-17-19-29(20-18-28)35-25-34(27-52-41-43-38(30-11-5-3-6-12-30)39(51-41)31-13-7-4-8-14-31)49-40(50-35)32-21-23-33(24-22-32)42-36(46)15-9-1-2-10-16-37(47)44-48/h3-8,11-14,17-24,34-35,40,45,48H,1-2,9-10,15-16,25-27H2,(H,42,46)(H,44,47)/t34-,35+,40+/m1/s1
InChI Key:
BHUZLJOUHMBZQY-YXQOSMAKSA-N
Properties
Complexity:
1060
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
3
Defined Bond Stereocenter Count:
0
Exact Mass:
721.282g/mol
Formal Charge:
0
Heavy Atom Count:
52
Hydrogen Bond Acceptor Count:
9
Hydrogen Bond Donor Count:
4
Isotope Atom Count:
0
Molecular Weight:
721.869g/mol
Monoisotopic Mass:
721.282g/mol
Rotatable Bond Count:
16
Topological Polar Surface Area:
168A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
6.3
Literature
| Title | Journal |
|---|---|
| Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca(2+) in knock-out mouse models of polycystic kidney disease. | The Journal of biological chemistry 20171027 |
| Grouping of histone deacetylase inhibitors and other toxicants disturbing neural crest migration by transcriptional profiling. | Neurotoxicology 20150901 |
| Development and therapeutic implications of selective histone deacetylase 6 inhibitors. | Journal of medicinal chemistry 20130822 |
| Taxol alleviates 2-methoxyestradiol-induced endothelial permeability. | Vascular pharmacology 20120101 |
| The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity. | Bioorganic & medicinal chemistry letters 20111015 |
| p62/SQSTM1 in autophagic clearance of a non-ubiquitylated substrate. | Journal of cell science 20110815 |
| Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. | Journal of the American Chemical Society 20100811 |
| The influence of mediators of intracellular trafficking on transgene expression efficacy of polymer-plasmid DNA complexes. | Biomaterials 20100801 |
| Acetylation of microtubules influences their sensitivity to severing by katanin in neurons and fibroblasts. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20100526 |
| Chemical phylogenetics of histone deacetylases. | Nature chemical biology 20100301 |
| Expansion of the trans-Golgi network following activated collagen secretion is supported by a coiled-coil microtubule-bundling protein, p180, on the ER. | Experimental cell research 20100201 |
| HDAC6 regulates mitochondrial transport in hippocampal neurons. | PloS one 20100101 |
| The NIMA-family kinase Nek3 regulates microtubule acetylation in neurons. | Journal of cell science 20090701 |
| Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis. | The Journal of biological chemistry 20090619 |
| Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20090201 |
| Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081115 |
| Structural origin of selectivity in class II-selective histone deacetylase inhibitors. | Journal of medicinal chemistry 20080522 |
| Fold up or perish: unfolded protein response and chemotherapy. | Cell death and differentiation 20080201 |
| Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. | Oncogene 20050630 |
| Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. | Journal of medicinal chemistry 20050505 |
| Structural biasing elements for in-cell histone deacetylase paralog selectivity. | Journal of the American Chemical Society 20030514 |
| Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. | Chemistry & biology 20030501 |
| Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. | Proceedings of the National Academy of Sciences of the United States of America 20030415 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.